Enavermotide (UCP2) is an immunological agent for active immunization (antineoplastic)[1].
References
[1] Godet Y, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012 May 15;18(10):2943-53. DOI:10.1158/1078-0432.CCR-11-3185
